ALDAGEN

Aldagen is a biopharmaceutical company developing proprietary regenerative cell therapies that target significant unmet medical needs. The company's most advanced product candidates are ALD-101, ALD-301 and ALD-201. Aldagen is currently conducting a pivotal Phase 3 clinical trial of ALD-101 for improving umbilical cord blood transplants used to treat inherited metabolic diseases in pediatric patients. The company is also preparing to commence a pivotal Phase 3 clinical trial of ALD-301 in treating critical limb ischemia and is developing ALD-201 for the treatment of ischemic heart failure. Aldagen is pursuing the development of additional product candidates based on the company's proprietary technology for isolating adult stem cells that express high levels of ALDH, including products to improve cord blood transplants used to treat leukemias, for the treatment of inherited metabolic diseases and for the post-acute treatment of ischemic stroke.

12.08.09 - Download PDF
Aldagen Announces Data Presented at American Society of Hematology Annual Meeting

11.18.09 - Download PDF
Aldagen Announces Clinical Data for ALD-201 for Ischemic Heart Failure Presented at AHA

11.16.09 - Download PDF
Phase 1/2 Results for Aldagen's ALD-301 Critical Limb Ischemia Clinical Study Presented at AHA